Imugene: Receives ethics approval for PD1-Vaxx trial
- Biotech company Imugene has received Human Research Ethics Committee (HREC) approval to begin a phase one clinical trial of PD1-Vaxx in Australia
- This trial will also completed under Australia’s Clinical Trials Notification (CTN) Scheme and patient screening scheduled to begin in August
- Then the aim of this trial is to determine the safety, efficacy, tolerability, and optimal dose
- PD1-Vaxx used to treat tumours such as lung cancer by obstructing programmed death-ligand one (PD-1/PD-L1) and producing an anti-cancer effect
- PD-1/PD-L1 is a type of protein that plays a role in suppressing the adaptive arm of the immune system
- Imugene is up a slight 2.94 per cent on the market and shares are currently trading for 3.5 cents each
